Northern Trust Corp Seres Therapeutics, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 218,222 shares of MCRB stock, worth $120,022. This represents 0.0% of its overall portfolio holdings.

Number of Shares
218,222
Previous 721,758 69.77%
Holding current value
$120,022
Previous $519,000 60.12%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$0.7 - $1.48 $352,475 - $745,233
-503,536 Reduced 69.77%
218,222 $207,000
Q2 2024

Aug 14, 2024
SELL
$0.56 - $1.19 $35,243 - $74,892
-62,935 Reduced 8.02%
721,758 $519,000
Q1 2024

May 14, 2024
BUY
$0.75 - $1.56 $10,561 - $21,967
14,082 Added 1.83%
784,693 $604,000
Q4 2023

Feb 13, 2024
SELL
$0.93 - $2.15 $141,406 - $326,907
-152,050 Reduced 16.48%
770,611 $1.08 Million
Q3 2023

Nov 13, 2023
SELL
$2.33 - $5.07 $5,829 - $12,685
-2,502 Reduced 0.27%
922,661 $2.2 Million
Q2 2023

Aug 11, 2023
BUY
$4.67 - $6.55 $861,563 - $1.21 Million
184,489 Added 24.91%
925,163 $4.43 Million
Q1 2023

May 15, 2023
BUY
$4.95 - $6.09 $50,608 - $62,264
10,224 Added 1.4%
740,674 $4.2 Million
Q4 2022

Feb 13, 2023
SELL
$5.09 - $9.05 $20,517 - $36,480
-4,031 Reduced 0.55%
730,450 $4.09 Million
Q3 2022

Nov 14, 2022
BUY
$3.5 - $7.2 $201,855 - $415,245
57,673 Added 8.52%
734,481 $4.72 Million
Q2 2022

Aug 12, 2022
SELL
$2.7 - $7.62 $64,654 - $182,468
-23,946 Reduced 3.42%
676,808 $2.32 Million
Q1 2022

May 13, 2022
SELL
$6.3 - $8.84 $235,626 - $330,624
-37,401 Reduced 5.07%
700,754 $4.99 Million
Q4 2021

Feb 08, 2022
BUY
$6.02 - $11.43 $341,213 - $647,852
56,680 Added 8.32%
738,155 $6.15 Million
Q3 2021

Nov 15, 2021
SELL
$5.46 - $22.6 $183,630 - $760,083
-33,632 Reduced 4.7%
681,475 $4.74 Million
Q2 2021

Aug 13, 2021
BUY
$18.46 - $24.36 $1.34 Million - $1.77 Million
72,501 Added 11.28%
715,107 $17.1 Million
Q1 2021

May 12, 2021
SELL
$17.66 - $28.92 $754,276 - $1.24 Million
-42,711 Reduced 6.23%
642,606 $13.2 Million
Q4 2020

Feb 11, 2021
BUY
$23.25 - $37.73 $748,185 - $1.21 Million
32,180 Added 4.93%
685,317 $16.8 Million
Q3 2020

Nov 16, 2020
BUY
$3.74 - $28.74 $374,190 - $2.88 Million
100,051 Added 18.09%
653,137 $18.5 Million
Q2 2020

Aug 14, 2020
BUY
$3.04 - $6.2 $254,177 - $518,388
83,611 Added 17.81%
553,086 $2.63 Million
Q1 2020

May 14, 2020
BUY
$2.64 - $3.82 $24,713 - $35,759
9,361 Added 2.03%
469,475 $1.68 Million
Q4 2019

Feb 14, 2020
SELL
$2.99 - $4.42 $45,749 - $67,630
-15,301 Reduced 3.22%
460,114 $1.59 Million
Q3 2019

Nov 13, 2019
BUY
$2.29 - $4.16 $488,104 - $886,687
213,146 Added 81.27%
475,415 $1.91 Million
Q2 2019

Aug 13, 2019
BUY
$2.28 - $7.35 $24,106 - $77,711
10,573 Added 4.2%
262,269 $844,000
Q1 2019

May 13, 2019
BUY
$4.83 - $7.21 $9,819 - $14,657
2,033 Added 0.81%
251,696 $1.73 Million
Q4 2018

Feb 12, 2019
SELL
$4.52 - $8.88 $8,027 - $15,770
-1,776 Reduced 0.71%
249,663 $1.13 Million
Q3 2018

Nov 14, 2018
BUY
$7.33 - $9.23 $37,595 - $47,340
5,129 Added 2.08%
251,439 $1.91 Million
Q2 2018

Sep 18, 2018
SELL
$6.91 - $9.55 $17,993 - $24,868
-2,604 Reduced 1.05%
246,310 $2.12 Million
Q2 2018

Aug 14, 2018
BUY
$6.91 - $9.55 $114,878 - $158,768
16,625 Added 7.16%
248,914 $2.14 Million
Q1 2018

May 09, 2018
SELL
$7.34 - $11.16 $1,710 - $2,600
-233 Reduced 0.1%
232,289 $1.71 Million
Q4 2017

Feb 14, 2018
SELL
$9.15 - $12.64 $45,493 - $62,846
-4,972 Reduced 2.09%
232,522 $2.36 Million
Q3 2017

Nov 13, 2017
BUY
$12.81 - $16.85 $3.04 Million - $4 Million
237,494
237,494 $3.81 Million

Others Institutions Holding MCRB

# of Institutions
82
Shares Held
40.5M
Call Options Held
304K
Put Options Held
471K
View Full List

About Seres Therapeutics, Inc.

MCRB Quotes by TradingView
  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $68.2M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email